Table III.
Univariate and multivariate analyses of variable factors of response in previously treated NSCLC patients treated with nivolumab.
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
| Characteristic | RR (%) | OR | 95% CI | P-value | OR | 95% CI | P-value |
| Age, years | |||||||
| <70 | 26.5 | 0.56 | 0.08–2.74 | 0.51 | |||
| ≥70 | 16.7 | ||||||
| Sex | |||||||
| Male | 24.3 | 1.27 | 0.26–8.63 | 1.00 | |||
| Female | 20.0 | ||||||
| PS | |||||||
| <2 | 23.4 | 0.82 | 0.02–9.53 | 1.00 | |||
| ≥2 | 20.0 | ||||||
| Histology | |||||||
| SQC | 30.8 | 1.70 | 0.30–8.39 | 0.47 | 1.27 | 0.27–6.11 | 0.76 |
| Other | 20.5 | ||||||
| EGFR mutations | |||||||
| Yes | 0 | 0 | 0–1.35 | 0.09 | 0.00 | 0.00-NR | 0.99 |
| No | 28.6 | ||||||
| Lines of chemotherapy | |||||||
| 2 or 3 | 36.7 | 11.67 | 1.45–546.00 | 0.01 | |||
| ≥4 | 4.5 | ||||||
| Smoking status | |||||||
| Current/former | 23.9 | 1.56 | 0.15–80.96 | 1.00 | 0.24 | 0.01–4.49 | 0.34 |
| Never | 16.7 | ||||||
| Use of statin | |||||||
| Yes | 62.5 | 8.29 | 1.29–66.58 | 0.01 | 7.37 | 1.35–40.10 | 0.02 |
| No | 15.9 | ||||||
| Use of fibrate | |||||||
| Yes | 50.0 | 3.42 | 0.04–284.54 | 0.41 | |||
| No | 22.0 | ||||||
| Use of DPP-4 inhibitor | |||||||
| Yes | 25.0 | 1.12 | 0.020–15.64 | 1.00 | |||
| No | 22.9 | ||||||
| Use of metformin | |||||||
| Yes | 100 | Inf | 0.09-Inf | 0.23 | |||
| No | 21.6 | ||||||
RR, response rate; OR, odds ratio; PS, performance status; SQC, squamous cell carcinoma; NR, not reached; CI, confidence interval; EGFR, epidermal growth factor receptor; DPP-4, dipeptidyl peptidase4; Inf, infinity.